Curexo Inc. (KOSDAQ:060280)
South Korea · Delayed Price · Currency is KRW 9,990.00
+20.00 (0.20%)
Nov 19, 2025, 3:30 PM KST
Curexo Revenue
Curexo had revenue of 17.23B KRW in the quarter ending September 30, 2025, with 27.49% growth. This brings the company's revenue in the last twelve months to 27.85B, down -3.00% year-over-year. In the year 2015, Curexo had annual revenue of 27.53B with 5.33% growth.
Revenue (ttm)
27.85B
Revenue Growth
-3.00%
P/S Ratio
14.74
Revenue / Employee
960.27M
Employees
29
Market Cap
410.49B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2015 | 27.53B | 1.39B | 5.33% |
| Dec 31, 2014 | 26.14B | -4.95B | -15.93% |
| Dec 31, 2013 | 31.09B | 6.81B | 28.05% |
| Dec 31, 2012 | 24.28B | 13.74B | 130.32% |
| Dec 31, 2011 | 10.54B | -21.61B | -67.21% |
| Dec 31, 2010 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2009 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2008 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2006 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.50T |
| SK Biopharmaceuticals | 620.28B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |